Skip to main content
Advertisement
Advertisement
ARMP
ARMP logo
Armata Pharmaceuticals, Inc. Common Stock
3.51
USD
Sponsored
+0.51
+17.00%
Nov 06, 15:59 UTC -5
Closed
exchange

After-Market

3.48

-0.03
-0.85%

Armata Pharmaceuticals, Inc. Common Stock (ARMP) Earnings

ARMP Earnings Reports

Positive Surprise Ratio

ARMP beat 21 of 41 last estimates.

51%

Next Report

Date of Next Report
Nov 18, 2026
Estimate for Q3 26 (Revenue/ EPS)
$459.00K
/
-$0.56
Implied change from Q2 26 (Revenue/ EPS)
-81.71%
/
+107.41%
Implied change from Q3 25 (Revenue/ EPS)
-60.40%
/
-24.32%

Armata Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Aug 12, 2026, ARMP reported earnings of -0.27 USD per share (EPS) for Q2 26, beating the estimate of -0.45 USD, resulting in a 40.52% surprise. Revenue reached 2.51 million, compared to an expected 428.40 thousand, with a 485.90% difference. The market reacted with a +11.83% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.56 USD, with revenue projected to reach 459.00 thousand USD, implying an increase of 107.41% EPS, and decrease of -81.71% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Intellia Therapeutics, Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.81
Actual
-$0.91
Surprise
-11.97%
logo
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
logo
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
logo
Starling Oncology, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.04
Actual
-$0.13
Surprise
-165.31%
logo
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
logo
Tectonic Therapeutic, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.35
Actual
-$1.08
Surprise
+20.37%
logo
SAB Biotherapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
logo
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
logo
Cognition Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.04
Surprise
+41.18%
logo
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
FAQ
For Q2 2026, Armata Pharmaceuticals, Inc. Common Stock reported EPS of -$0.27, beating estimates by 40.52%, and revenue of $2.51M, 485.9% above expectations.
The stock price moved up 11.83%, changed from $4.31 before the earnings release to $4.82 the day after.
The next earning report is scheduled for Nov 18, 2026.
Based on -- analysts, Armata Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.56 and revenue of $459.00K for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement